Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eliav Barr

Showing results (11-20 of 74) with videos related to

Pageof 8
Sort By:
Vaccine|April 21, 2007
Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccineChristophe Fraser, Joanne E Tomassini, Liwen Xi, et al.
Gerontology & Geriatric Medicine|March 21, 2019
Efficacy and Safety of Elbasvir/Grazoprevir in Hepatitis C Virus GT1- and GT4-Infected People Aged 65 Years or OlderSteven Flamm, Cheng-Yuan Peng, Oren Shibolet, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 17, 2006
Smokers at higher risk for undetected antibody for oncogenic human papillomavirus type 16 infectionDorothy J Wiley, Edward Wiesmeier, Emmanuel Masongsong, et al.
The Journal of Infectious Diseases|February 10, 2009
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccineSuzanne M Garland, Marc Steben, Heather L Sings, et al.
Human Vaccines|July 6, 2007
Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirionsJudith F Smith, Michelle Brownlow, Martha Brown, et al.
American Journal of Obstetrics and Gynecology|March 4, 2008
Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American womenEliav Barr, Christine K Gause, Oliver M Bautista, et al.
The New England Journal of Medicine|November 22, 2002
A controlled trial of a human papillomavirus type 16 vaccineLaura A Koutsky, Kevin A Ault, Cosette M Wheeler, et al.
Antiviral Therapy|July 25, 2018
Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infectionFrederick Lahser, Angela Galloway, Peggy Hwang, et al.
Archives of Gynecology and Obstetrics|October 22, 2008
Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccineElisabeth Barthell, Linn Woelber, Karin Hellner, et al.
Hepatology Communications|February 7, 2018
Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infectionNancy Reau, Michael N Robertson, Hwa-Ping Feng, et al.
Pageof 8

Showing results (11-20 of 74) with videos related to

Sort By:
Pageof 8
Vaccine|April 21, 2007
Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccineChristophe Fraser, Joanne E Tomassini, Liwen Xi, et al.
Gerontology & Geriatric Medicine|March 21, 2019
Efficacy and Safety of Elbasvir/Grazoprevir in Hepatitis C Virus GT1- and GT4-Infected People Aged 65 Years or OlderSteven Flamm, Cheng-Yuan Peng, Oren Shibolet, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 17, 2006
Smokers at higher risk for undetected antibody for oncogenic human papillomavirus type 16 infectionDorothy J Wiley, Edward Wiesmeier, Emmanuel Masongsong, et al.
The Journal of Infectious Diseases|February 10, 2009
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccineSuzanne M Garland, Marc Steben, Heather L Sings, et al.
Human Vaccines|July 6, 2007
Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirionsJudith F Smith, Michelle Brownlow, Martha Brown, et al.
American Journal of Obstetrics and Gynecology|March 4, 2008
Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American womenEliav Barr, Christine K Gause, Oliver M Bautista, et al.
The New England Journal of Medicine|November 22, 2002
A controlled trial of a human papillomavirus type 16 vaccineLaura A Koutsky, Kevin A Ault, Cosette M Wheeler, et al.
Antiviral Therapy|July 25, 2018
Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infectionFrederick Lahser, Angela Galloway, Peggy Hwang, et al.
Archives of Gynecology and Obstetrics|October 22, 2008
Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccineElisabeth Barthell, Linn Woelber, Karin Hellner, et al.
Hepatology Communications|February 7, 2018
Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infectionNancy Reau, Michael N Robertson, Hwa-Ping Feng, et al.
Pageof 8